Medidata Expands Agreement With Worldwide Clinical Trials
Expanded relationship will utilize Medidata’s artificial intelligence solutions.
Medidata and Worldwide Clinical Trials have announced an expansion of their existing relationship. The new agreement will implement Medidata AI, enabling Worldwide to further reduce trial timelines and improve site selection.1
“Worldwide will accelerate clinical research and advance the life sciences industry by leveraging site-level granularity and real-time actionable observations provided by Medidata AI’s turnkey solution,” Tom Doyle, chief technology officer, Medidata, said in a press release.
"For over 10 years, we’ve partnered with Medidata to help our customers gather advanced, data-driven insights so they can make confident and well-informed decisions about the future direction of their clinical trials,” Peter Benton, president and CEO, Worldwide Clinical Trials said in the press release. “Incorporating Medidata AI Intelligent Trials into our studies will allow us to more systematically plan, design, and execute research so we can deliver a better experience for patients and sponsors.”
Medidata AI appeared in the news earlier this year as well, when Medidata renewed its relationship with the PPD clinical research business of Thermo Fisher Scientific Inc. A key element of this collaboration is the evolution of PPD TrueCast, a business solution powered by Medidata AI, which combines patient recruitment and site performance data to deliver predictive models and advanced analytics.2
In addition to Medidata AI, the new agreement with PPD featured the Medidata Platform, Medidata Adjudicate, and additional Medidata Rave product offerings. The duo has been working together on clinical studies for biopharmaceutical and medical device companies since 2009.
References
1. Medidata Selected by Worldwide Clinical Trials to Accelerate Trials and Transform Patient Experience. News release. May 14, 2024. Accessed May 14, 2024. https://www.3ds.com/newsroom/press-releases/medidata-selected-worldwide-clinical-trials-accelerate-trials-and-transform-patient-experience
2. Medidata and Thermo Fisher Scientific’s PPD Clinical Research Business Collaborate to Accelerate Clinical Trials Innovation. News release. February 28, 2024. Accessed May 14, 2024. https://www.medidata.com/en/about-us/news-and-press/medidata-and-thermo-fisher-scientifics-ppd-clinical-research-business-collaborate-to-accelerate-clinical-trials-innovation/
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
First Patient Dosed in Phase III Trial of Enhertu as First-Line Treatment for Endometrial Cancer
June 10th 2025In combination with rilvegostomig or Keytruda, Enhertu will be evaluated versus chemotherapy in the DESTINY-Endometrial01 study for the treatment of patients with HER2-expressing, mismatch repair proficient primary advanced or recurrent endometrial cancer.
